Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. [electronic resource]
Producer: 20130115Description: 668-77 p. digitalISSN:- 1365-2133
- Administration, Oral
- Adult
- Chronic Disease
- Dermatologic Agents -- administration & dosage
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Humans
- Janus Kinase 3 -- antagonists & inhibitors
- Male
- Piperidines
- Psoriasis -- drug therapy
- Pyrimidines -- administration & dosage
- Pyrroles -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.